Basic Information
Kynexis is developing a precision medicine to treat cognitive impairments associated with schizophrenia. The company's research is based on using human biology-driven approaches as its targeting principle, employing a causal biomarker approach to determine its mechanism of action in clinical development, and utilizing human genetics methods to identify responsive subpopulations, enabling schizophrenia patients to restore their brain function.